Clinical Trials Logo

Clinical Trial Summary

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with lymphodepletion and high-dose interleukin 2.

Most TIL ACT trials have been conducted as salvage therapy for patients who already had failed numerous treatments; many study participants presented with multiple metastases, frequently in visceral organs and even in the brain. The effectiveness of TIL ACT in eradicating metastatic tumors of the responding patients underlines the value of this immunotherapeutic approach.

Recent developments in the identification and selection of tumor-specific T-cell populations have facilitated the implementation of TIL ACT also in nonmelanoma malignancies. Building on the experience of Ella Lemelbaum Institute, Sheba Medical Center with ACT TIL in the treatment of metastatic melanoma, the Dept. of Oncology, Tel HaShomer has expanded the use of TIL ACT following a reduced intensity, non-myeloablative, lymphodepleting induction regimen to metastatic Melanoma, Ovarian (OC) and Cervical cancer patients. The rationale supporting these studies is to further develop the ACT TIL procedure and expand its applicability to metastatic OC and cervical cancers.


Clinical Trial Description

The Sponsor is developing the ex-vivo expanded autologous Tumor Infiltrating Lymphocytes (TIL) as the Investigational Product (IP). Yet, the administration of the TIL cellular product can only be accomplished in the context of an Autologous, Adoptive Cell Therapy (ACT) procedure which is composed of the following steps:

1. Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Fludarabine (25 mg/m2 for 3 days) followed by Total Body Radiation (TBR) (2 Gray as a single treatment) for 1 day

2. Preparation and administration of unselected or 4-1BB enriched TIL

3. Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.

4. Early-stage follow-up until 30 days post-discharge

5. Late-stage follow-up, such as CT scans, will be carried out four and twelve weeks after TIL administration, and then every 3 months thereafter for the first year after TIL therapy; for the second year and onwards, as clinically indicated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03412526
Study type Interventional
Source Sheba Medical Center
Contact Jacob Scachter, Prof.
Phone 972-3-5304907
Email jacob.schachter@sheba.health.gov.il
Status Recruiting
Phase Phase 2
Start date January 21, 2018
Completion date February 1, 2022

See also
  Status Clinical Trial Phase
Withdrawn NCT03634150 - Safety and Efficacy of IV Nerofeā„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer Phase 1/Phase 2
Completed NCT01768156 - Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer N/A
Completed NCT03287674 - TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer Phase 1/Phase 2
Recruiting NCT05796973 - Measuring Oncological Value of Exercise and Statin Phase 3
Terminated NCT03277482 - Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer Phase 1
Completed NCT02482090 - TIL Therapy for Metastatic Ovarian Cancer Phase 1
Recruiting NCT03150992 - EDMONd - Elemental Diet in Bowel Obstruction N/A
Recruiting NCT01174121 - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Phase 2
Recruiting NCT04611126 - T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer Phase 1/Phase 2
Completed NCT03242993 - [18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging Phase 1